Breaking News

Tweet TWEET

Improving Clinical Outcomes, Expanded Services, Earnings Schedule and Guidance - Research Report on Abbott, Baxter, PerkinElmer,

Improving Clinical Outcomes, Expanded Services, Earnings Schedule and Guidance
   - Research Report on Abbott, Baxter, PerkinElmer, Allscripts and Parexel

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 10, 2013

NEW YORK, July 10, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Abbott
Laboratories (NYSE: ABT), Baxter International Inc. (NYSE: BAX), PerkinElmer
Inc. (NYSE: PKI), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) and
PAREXEL International Corporation (NASDAQ: PRXL). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Abbott LaboratoriesResearch Report

On June 20, 2013, Abbott Laboratories (Abbott) introduced the first
FDA-approved hepatitis C virus (HCV) genotyping test for patients in the U.S.,
which provides physicians with important information they can use to create a
personalized, targeted diagnosis and treatment path to improve clinical
outcomes. "The Abbott RealTime HCV Genotype II test adds yet another test to
the Abbott portfolio for a full spectrum of hepatitis C testing from ensuring
blood supply safety and providing initial screening to enabling targeted
diagnoses, identification of the right treatments, and the monitoring of
response to therapies," said John Coulter, Vice President, Molecular
Diagnostics, Abbott. "Abbott continues to expand diagnostic testing options in
the infectious disease area to benefit the healthcare system and enable
doctors to improve patient care." The Full Research Report on Abbott
Laboratories - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0bcf_ABT]

--

Baxter International Inc.Research Report

On July 5, 2013, Baxter International Inc. (Baxter) presented ADVATE
[Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] data on
Prophylaxis Management and Efficacy for Hemophilia A, during the 24th Annual
Congress of the International Society on Thrombosis and Haemostasis (ISTH) in
Amsterdam. According to Baxter, the first study identifies a correlation
between peak levels of factor VIII in the body and the efficacy of treatment,
indicating that frequency of peaks may be important when choosing hemophilia
treatments. A second presentation suggested that for both hemophilia patients
and parents, efficacy through reduction in bleeds considerably outweighs
infusion convenience as the primary treatment priority. "Overall, these
studies emphasize that with regard to hemophilia patient care regimens,
treatment is simply not a 'one size fits all' approach, and individualized
regimens can help optimize the effectiveness each patient achieves," said
Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development
in Baxter's BioScience business. "Meeting the needs of individual patients and
raising the standard of care are the primary focus of Baxter's long-term
commitment in hemophilia and our pursuit of a future where one day, every
patient can live a life without bleeds." The Full Research Report on Baxter
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/103a_BAX]

--

PerkinElmer Inc.Research Report

On July 5, 2013, PerkinElmer Inc. (PerkinElmer) announced its earnings call
schedule. The Company will release its Q2 2013 results on Thursday, August 1,
2013, after the market close. Following the release of the results, the
Company will host a conference call on the same day at 5:00 p.m. ET. Robert F.
Friel, the Company's Chairman and Chief Executive Officer will host the
conference call together with, Andy Wilson, Senior Vice President and Chief
Financial Officer. A live audio webcast of the call will also be available on
the investor section of the Company's Web site. Further, on June 13, 2013, the
Company's Board of Directors had declared a quarterly dividend of $0.07 per
share of common stock, payable on August 9, 2013, to all shareholders of
record at the close of business on July 19, 2013. The Full Research Report on
PerkinElmer Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/2d16_PKI]

--

Allscripts Healthcare Solutions, Inc.Research Report

On July 1, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) and
Liberty Hospital announced an agreement for Allscripts to manage Liberty
Hospital's information technology (IT) services. "Allscripts is a global
company that has deep IT expertise," commented David Feess, President and
Chief Executive Officer of Liberty Hospital. "By combining our team with
theirs, we will be able to put long-term strategies and systems in place that
will last far into our future." Liberty Hospital currently has 30 employees
managing the computer information systems and IT programs at the hospital,
clinics and affiliates, and with the new agreement, these employees will
transfer to the Allscripts staff and be managed by Kelly Dungee, Liberty
Hospital Interim Chief Information Officer. The Full Research Report on
Allscripts Healthcare Solutions, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/1d85_MDRX]

--

PAREXEL International CorporationResearch Report

On June 25, 2013, PAREXEL International Corp. (Parexel) announced its earnings
expectations for Q4 FY 2013, full-year FY 2013 and full-year FY 2014. The
Company reaffirmed its guidance for Q4 FY 2013, anticipating consolidated
service revenue in the range of $449 to $459 million and GAAP diluted EPS of
$0.40 to $0.44. For full-year FY 2013, the Company continues to expect
consolidated service revenue to be in the range of $1,720 to $1,730 million,
and GAAP earnings per diluted share to be between $1.51 to $1.55, and adjusted
earnings per diluted share to be in the range of $1.60 to $1.64. Further, the
Company issued guidance estimates for FY 2014, anticipating consolidated
service revenue in the range of $1,885 to $1,915 million, and GAAP earnings
per diluted share between $1.90 and $2.10. The Full Research Report on PAREXEL
International Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/037f_PRXL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.